Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.

Future oncology (London, England) - 1 Jun 2007

Rosell Rafael, Taron Miquel, Sanchez Jose Javier, Paz-Ares Luis

Abstract excerpt

Overexpression and mutational activation of the epidermal growth factor receptor (EGFR) is involved in tumor development and progression in non-small-cell lung cancer (NSCLC). Somatic mutations in the EGFR kinase domain confer high sensitivity to tyrosine kinase inhibitors (TKIs). The two most frequent mutations are the exon 19 deletion and the exon 21 L858R. Distinct EGFR mutations differ in their effect on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bronchoscopy
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Ultrasonography

Source

Identifiers

PMID: 17547522
DOI: 10.2217/14796694.3.3.277

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.PMID 17547522Read ↗

Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations.Semantic proximity Read ↗

Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung CancerSemantic proximity Read ↗

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.Semantic proximity Read ↗

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.Semantic proximity Read ↗

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study.Semantic proximity Read ↗

Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain.Semantic proximity Read ↗

Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.Semantic proximity Read ↗

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.Semantic proximity Read ↗

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.Semantic proximity Read ↗

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.Semantic proximity Read ↗

Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.Semantic proximity Read ↗

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.